The drug works by blocking activation of a molecule called epidermal growth factor receptor, which causes tumor cells to grow.

In the trial, epidermal growth factor receptor showed a rapid response to the inhibitor, as demonstrated by the improvement of the cancer symptoms.

Furthermore, epidermal growth factor receptor plays a crucial role in tumorigenesis, which is the production of a new tumor.

GAPVD1 is also involved in the degradation of the epidermal growth factor receptor.

Erlotinib inhibits epidermal growth factor receptor, and works through a similar mechanism as gefitinib.

Cetuximab (marketed as Erbitux) targets the epidermal growth factor receptor.

That's short for "human epidermal growth factor receptor 2."

The lack of understanding is shown in the case of drugs that block the epidermal growth factor receptor.

This endosomal protein regulates the cell-surface expression of epidermal growth factor receptor.

Both drugs aim to block a cancer-spurring protein called epidermal growth factor receptor.